VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Aug 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-08-02

Reporting Person: SMITH IAN F (EVP, CFO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-02	Common Stock	M	2155	$91.05	Acquired	118043	Direct
2017-08-02	Common Stock	S	500	$152.49	Disposed	117543	Direct
2017-08-02	Common Stock	S	500	$153.57	Disposed	117043	Direct
2017-08-02	Common Stock	S	700	$154.55	Disposed	116343	Direct
2017-08-02	Common Stock	S	455	$156.09	Disposed	115888	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-02	Stock Option (Right to Buy)	$91.05	M	2155	Disposed	2026-02-01	Common Stock (2155)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5306	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $152.49 (range $152.00 to $152.76).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $153.57 (range $153.08 to $154.05).

F5: Open market sales reported on this line occurred at a weighted average price of $154.55 (range $154.20 to $154.93).

F6: Open market sales reported on this line occurred at a weighted average price of $156.09 (range $155.49 to $156.40).

F7: The option vests in 16 quarterly installments from 2/2/2016.